SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

WAMBIER, Carlos Gustavo; PEREIRA, Caroline Silva; PRADO JUNIOR, Benedito de Pina Almeida  and  FOSS, Norma Tiraboschi. Brazilian blood donation eligibility criteria for dermatologic patients. An. Bras. Dermatol. [online]. 2012, vol.87, n.4, pp. 590-595. ISSN 0365-0596.  http://dx.doi.org/10.1590/S0365-05962012000400012.

    1. Brasil. Ministério da Saúde. Portaria n 1.353, de 13 de junho de 2011. Aprova o Regulamento Técnico de Procedimentos Hemoterápicos. Diário Oficial [da] República Federativa do Brasil. 2011 jun 14; Seção 1. p.27-45. [ Links ]

    2. Brasil. Agência Nacional de Vigilância Sanitária. Resolução - RDC n 153, de 14 de junho de 2004. Determina o Regulamento Técnico para os procedimentos hemoterápicos, incluindo a coleta, o processamento, a testagem, o armazenamento, o transporte, o controle de qualidade e o uso humano de sangue, e seus componentes, obtidos do sangue venoso, do cordão umbilical, da placenta e da medula óssea. Diário Oficial [da] República Federativa do Brasil. 2004 jun. 25; Seção 1. p.68-83. [ Links ]

    3. Vieira FMJ, Martins JEC. Porfiria cutânea tardia. An Bras Dermatol. 2006;81: 573-84. [ Links ]

    4. Ramsay CA, Magnus IA, Turnbull A, Baker H. The treatment of porphyria cutanea tarda by venesection. Q J Med. 1974;43:1-24. [ Links ]

    5. Elder GH, Worwood M. Mutations in the hemochromatosis gene, porphyria cutanea tarda and iron overload. Hepatology. 1998;27:289-91. [ Links ]

    6. Elder GH. Porphyria cutanea tarda. Semin Liver Dis. 1998;18:67-75. [ Links ]

    7. Quecedo L, Costa J, Enríquez de Salamanca R. [Role of hepatitis C virus in porphyria cutanea tarda hepatopathy]. Med Clin (Barc). 1996;106:321-4. [ Links ]

    8. Navas S, Bosch P, Castillo I, Marriott E, Carreno V. Porphyria cutanea tarda and hepatitis C virus and B virus infection: a retrospective study. Hepatology. 1995;21:279-84. [ Links ]

    9. Mansourati FF, Stone VE, Mayer KH. Porphyria cutanea tarda and HIV/AIDS: a review of pathogenesis, clinical manifestations and management. Int J STD AIDS. 1999;10:51-6. [ Links ]

    10. Rich MW. Porphyria cutanea tarda. Don't forget to look at the urine. Postgrad Med. 1999;105:208-10, 213-4. [ Links ]

    11. Bickers DR, Pathak MA. The porphyrias. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF. Dermatology in General medicine. 4th ed. New York: McGraw-Hill; 1995. p.1854-93. [ Links ]

    12. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40:828-34. [ Links ]

    13. Fda.org [Internet]. Guidance for Industry: Variances for Blood Collection from Individuals with Hereditary Hemochromatosis. Food and Drug Administration; 2001. [cited 2012 Jan 5]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm080393.pdf. [ Links ]

    14. Sánchez-Pérez J, De Castro M, Buezo GF, Fernandez-Herrera J, Borque MJ, García- Díez A. Lichen planus and hepatitis C virus: prevalence and clinical presentation of patients with lichen planus and hepatitis C virus infection. Br J Dermatol. 1996;134:715-9. [ Links ]

    15. Vasconcellos MR, Castro LG, dos Santos MF. Soropositividade para HIV em doentes de herpes zoster. Rev Inst Med Trop Sao Paulo. 1990;32:364-9. [ Links ]

    16. Foss NT, Callera F, Alberto FL. Anti-PGL1 levels in leprosy patients and their contacts. Braz J Med Biol Res. 1993;26:43-51. [ Links ]

    17. Castro CO, Picon P, Arrais PS, Hoefler R. Uso racional de medicamentos: temas selecionados. Vol. 2. Brasília: OPAS-OMS/ Ministério da Saúde do Brasil; 2005. Capítulo 9, A volta da talidomida: qual é a evidência? p.1-6. [ Links ]

    18. Wolverton SE. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Elsevier; 2007. Chapter 26, Miscellaneous Systemic Drugs; p.488-94. [ Links ]

    19. Berbis P. Acitrétine. Ann Dermatol Venereol. 2001;128:737-45. [ Links ]

    20. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001;45:649-61. [ Links ]

    21. Grønhøj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol. 2000;143:1164-9. [ Links ]

    22. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: An overview of adverse effects. J Am Acad Dermatol. 1999;41:S7-12. [ Links ]

    23. Brasil. Agência Nacional de Vigilância Sanitária. Resolução - RDC n 343, de 13 de dezembro de 2002. Regulamento Técnico dos Serviços de Hemoterapia. Resolução. Diário Oficial [da] República Federativa do Brasil. 2002 dez 19; Seção1. p.133-43. [ Links ]

    24. AVODART® (dutasteride) - Prescribing information [Internet]. Food and Drug Administration; 2008. [cited 01 nov 2011]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021319s015lbl.pdf. [ Links ]